In addition to lightning-fast startup times, robust enrollment and full compliance with the ICH-GCP you will also be pleasantly surprised by the high quality of the study data evidenced by 12 recent 100% NAI (No Action Indicated) reports from FDA inspections.
Please follow the link to the whitepaper that may provide some additional insight into this issue.